SF

Shawnalea Frazier

Board of Directors at FireCyte Therapeutics

San Francisco, California

Overview

Work Experience

  • Director, West Coast Ventures

    2023 - Current

    AbbVie Ventures, AbbVie's strategic corporate venture capital arm investing in early stage opportunities in oncology, immunology, neuroscience, eye care and aesthetics. https://ventures.abbvie.com

  • Board of Directors

    2023

    Emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.

  • Board of Directors

    2023

    Pioneering biopharmaceutical company unlocking the therapeutic potential of nitrases, a new class of enzymes it discovered. Identification of Synuclein Nitrase is a new target for Parkinson’s disease therapeutics.

  • Board of Directors (Observer)

    2023

    • Nov 2023 -- Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients [https://www.trishulatx.com/news/#pr]

  • Board of Directors (Observer)

    2023

    Biotechnology company pioneering a new class of small molecule therapeutics that modulate the function of RNA to inhibit the production of disease-associated proteins.

  • Board of Directors (Observer)

    2023

    • Sept 2023 -- Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium [https://www.jnanatx.com/news/?pag=1]

  • Corporate Strategy Consultant

    2022 - 2023

    Immunology biotech startup spun out of Stanford University. • Feb 2023 -- IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy [https://iggenix.com/pressreleases/]

  • Principal

    2020 - 2022

    Novo Ventures (US), a Life Science Venture Capital firm investing in private and public biotech companies including therapeutics, medtech and digital health.

  • Senior Associate

    2018 - 2019

  • Associate

    2015 - 2017

  • Board of Directors (Observer)

    2017 - 2022

    • May 2021 -- Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial • Apr 2020 -- Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio • May 2017 -- Genoa Pharmaceuticals (fka) Secures $62 Million Series A Financing, Adds to Leadership Team [https://www.avalynpharma.com/news-events/news/]

  • Board of Directors (Observer)

    2018 - 2020

    • Oct 2020 -- Praxis Precision Medicines announces pricing of upsized initial public offering • July 2020 -- Praxis Precision Medicines announces $110 Million financing • May 2020 -- Praxis Precision Medicines launches with over $100 Million to advance pipeline of high impact therapies for brain disorders [https://investors.praxismedicines.com/press-releases]

Relevant Websites